MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Dissolving Jaw Syndrome With Cancer Drug

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Dissolving Jaw Syndrome With Cancer Drug

Dissolving Jaw Syndrome With Cancer Drug
Drugs belonging to the group of bisphosphonates like aredia are good in strengthening the bone in cancer patients including breast cancer. There is a downside to this group of drugs. These drugs can erode the jaw bone and literally dissolve the jaw bone.

This condition, called osteonecrosis of the jaw, is marked by exposed bone in the jaw and can lead to infection, inflammation and pain.

While scientists do not fully understand the condition or what causes it, osteonecrosis of the jaw, or ONJ, appears to occur in individuals who have been treated with drugs called bisphosphonates, which are used to improve bone strength. When treating bone affected by cancer, the bisphosphonates are given intravenously and have been shown to decrease the risk of skeletal complications such as fracture.

"Osteonecrosis of the jaw is not a common condition. It appears to occur in 1 percent to 10 percent of patients with advanced cancer who are on intravenous bisphosphonate treatment a number significant enough that most medical oncologists will see patients with this condition. It is important that scientists learn why it occurs and how best to prevent or treat it," says Catherine Van Poznak, M.D., assistant professor of internal medicine at the University of Michigan Medical School.

Van Poznak has authored two recent reviews of osteonecrosis of the jaw. One study appears in the recent issue of Current Opinions in Orthopaedics. The other was published in August in the journal Oncology. Both papers synthesize the present data for an overview of what is known to date about this recently identified complication.

ONJ is marked by exposed, non-healing bone. Pain, swelling and inflammation are the most common symptoms but the lesions can have no symptoms. ONJ typically develops months or years after treatment with intravenous bisphosphonates begins. Scientists have noted that when ONJ occurs, it commonly follows an invasive dental procedure such as an extraction where the wound does not heal in a normal fashion. To try to prevent ONJ, it has been suggested that patients maximize their oral health and take care of any invasive dental work before they begin bisphosphonate treatment.

"No reported therapy has proven successful for osteonecrosis of the jaw, which means for now the focus is on prevention or alleviating symptoms once it develops. We do not know how to predict who will develop ONJ or who is most at risk," says Van Poznak, a breast oncologist at the U-M Comprehensive Cancer Center who treats patients whose cancer has metastasized to bone.

"Some patients have resolution of the lesion but in other patients, it may remain stable or even progress," Van Poznak adds.

Patients with osteoporosis also take bisphosphonates, eventhough their therapy is typically prescribed as a pill, rather than intravenously. Some cases of ONJ have been reported in patients with osteoporosis who are taking oral bisphosphonates, but the risk of ONJ to such patients appears to be very low.

Prior studies have noted anywhere from 0.6 percent to 10 percent of patients with cancer on bisphosphonates developed ONJ. Reporting is currently voluntary. The problem, Van Poznak says, is that the condition itself is poorly defined and no universal reporting mechanism exists.

To address these challenges, clinical trials are being designed to help better define the condition. These upcoming clinical trials investigating bisphosphonate treatment for advanced cancer will include monitoring for ONJ, and scientists hope to learn what causes the condition to develop.


Posted by: Janet    Source




Did you know?
Drugs belonging to the group of bisphosphonates like aredia are good in strengthening the bone in cancer patients including breast cancer. There is a downside to this group of drugs. These drugs can erode the jaw bone and literally dissolve the jaw bone. This condition, called osteonecrosis of the jaw, is marked by exposed bone in the jaw and can lead to infection, inflammation and pain.

Medicineworld.org: Dissolving Jaw Syndrome With Cancer Drug

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.